General Biotechnologies engineers fast-growing cyanobacteria and other microbes as low-cost biomanufacturing platforms for peptide therapeutics
General Biotechnologies engineers fast-growing cyanobacteria and other microbes as low-cost biomanufacturing platforms for peptide therapeutics. Its Regenesis platform uses edible microbes to produce and orally deliver GLP-1 therapeutics. The company also develops genetic engineering toolkits for microbial strains, including UTEX 3222.